These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29526503)

  • 1. Engineering the immune system with particles, step-by-step.
    De Geest BG
    Mol Immunol; 2018 Jun; 98():25-27. PubMed ID: 29526503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
    Klippstein R; Pozo D
    Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle delivery systems in cancer vaccines.
    Krishnamachari Y; Geary SM; Lemke CD; Salem AK
    Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional nanoparticles for cancer immunotherapy.
    Saleh T; Shojaosadati SA
    Hum Vaccin Immunother; 2016 Jul; 12(7):1863-75. PubMed ID: 26901287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering nano- and microparticles to tune immunity.
    Moon JJ; Huang B; Irvine DJ
    Adv Mater; 2012 Jul; 24(28):3724-46. PubMed ID: 22641380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of nanoparticle vaccines as a treatment for cancer.
    Urbanavicius D; Alvarez T; Such GK; Johnston APR; Mintern JD
    Mol Immunol; 2018 Jun; 98():2-7. PubMed ID: 29395251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particulate vaccines: on the quest for optimal delivery and immune response.
    De Temmerman ML; Rejman J; Demeester J; Irvine DJ; Gander B; De Smedt SC
    Drug Discov Today; 2011 Jul; 16(13-14):569-82. PubMed ID: 21570475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of adjuvant formulations and delivery systems.
    García A; De Sanctis JB
    APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
    Nguyen TL; Choi Y; Kim J
    Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of exosomes as a nanoscale cancer vaccine.
    Tan A; De La Peña H; Seifalian AM
    Int J Nanomedicine; 2010 Nov; 5():889-900. PubMed ID: 21116329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug Delivery for Cancer Immunotherapy and Vaccines.
    Batty CJ; Tiet P; Bachelder EM; Ainslie KM
    Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants.
    Schijns VE
    Vaccine; 2003 Feb; 21(9-10):829-31. PubMed ID: 12547589
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
    Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
    ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomaterial Strategies for Immunomodulation.
    Hotaling NA; Tang L; Irvine DJ; Babensee JE
    Annu Rev Biomed Eng; 2015; 17():317-49. PubMed ID: 26421896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.